Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK, Chinese Firm In Flu Vaccine Venture
by Lisa M. Jarvis
June 15, 2009
| A version of this story appeared in
Volume 87, Issue 24
GlaxoSmithKline and Shenzhen Neptunus Interlong Bio-Technique have formed a joint venture to make flu vaccines for the Chinese market. GSK will pay $34 million in cash and assets for a 40% stake in the venture, with Neptunus putting up $50 million for the rest. GSK has the right to buy a majority interest in the joint venture within the next two years. Neptunus has knowledge of the local flu market, and GSK contributes its adjuvant technology and vaccine development experience.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X